PUT - SPRINTER OPEN END - ELI LILLY & CO | Delayed Deutsche Boerse AG 15:52:49 26/06/2024 BST | ||
| 4.79 EUR | 0.00% |
|
| Current month | -62.95% | ||
| 1 month | -63.93% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
More news
| Date | Price | Change |
|---|---|---|
| 26/06/24 | 4.79 | 0.00% |
| 25/06/24 | 4.79 | -8.59% |
| 24/06/24 | 5.24 | -17.87% |
| 21/06/24 | 6.38 | -12.48% |
| 20/06/24 | 7.29 | +33.27% |
Delayed Quote Deutsche Boerse AG
Last update June 26, 2024 at 03:52 pm
More quotesStatic data
| Product type | Knock-Out ohne Stop Loss |
|---|---|
| Buy / Sell | PUT |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Vontobel
|
| WKN | VD0KLB |
| ISIN | DE000VD0KLB3 |
| Date issued | 19/02/2024 |
| Strike | 953.3 $ |
| Maturity | Unlimited |
| Parity | 10 : 1 |
| Emission price | 15.6 € |
| Emission volume | N/A |
| Settlement | Barausgleich |
| Currency | EUR |
Technical Indicators
| Highest since issue | 21.75 € |
|---|---|
| Lowest since issue | 4.23 € |
| Spread | 0.03 € |
| Spread % | 0.64% |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
904.6
USD
Average target price
860.5
USD
Spread / Average Target
-4.87%
- Stock Market
- Certificates
- Certificat
